Isatuximab During Stem Cell Collection and Transplant in Patients With Multiple Myeloma and Lymphoma

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

PHASE2

Total Enrollment

39 participants

Study Classification

INTERVENTIONAL

Study Start Date

2023-03-31

Study Completion Date

2026-09-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to see if Isatuximab can alter the immune system in patients with multiple myeloma or lymphoma upon recovery from the autologous stem cell transplantation. The investigators will see if Isatuximab makes changes to the immune system so that upon recovery from the transplant, the immune system can fight the cancer. This study will have two arms. On one arm (control arm), participants will receive standard transplant procedures and on the other arm (experimental arm), participants will receive Isatuximab in addition to the standard transplant procedures. The assignment to these arms is done randomly (determined by chance, like flipping a coin) by a computer. Each participant will have about 66% chance of getting on the experimental arm and about 33% chance of getting on the control arm.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Open-Label, Phase II Trial of Isatuximab for Patients With Refractory Immune Cytopenias After Allogeneic Hematopoietic Cell Transplantation

NCT05873205

Blood Cancer Refractory Immune Cytopenias

RECRUITING PHASE2

Post-Transplant Maintenance Therapy With Isatuximab Plus Lenalidomide for High-Risk Multiple Myeloma Patients

NCT05776979

Multiple Myeloma

RECRUITING PHASE2

Id-KLH Vaccine + T Cells in Subjects With Myeloma Undergoing Transplant

NCT01426828

Multiple Myeloma

COMPLETED PHASE2

Rituximab in Treating Patients Undergoing Donor Peripheral Blood Stem Cell Transplant for Relapsed or Refractory B-cell Lymphoma

NCT00867529

B-cell Adult Acute Lymphoblastic Leukemia B-cell Childhood Acute Lymphoblastic Leukemia B-cell Chronic Lymphocytic Leukemia +35 more

COMPLETED PHASE2

Isatuximab With or Without Lenalidomide in Patients With High Risk Smoldering Multiple Myeloma (ISAMAR)

NCT02960555

Smoldering Plasma Cell Myeloma

ACTIVE_NOT_RECRUITING PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Relapse post-autologous stem cell transplantation (ASCT) remains a major challenge in the treatment of multiple myeloma (MM) and Lymphoma. The immune reconstitution post-ASCT has a major impact on the outcomes of ASCT, however effective methods to improve upon immune reconstitution have not been developed and the use of novel immunomodulators remains relatively unexplored. In addition, numerous studies have demonstrated the profound impact of graft composition on transplant outcomes, but not a single prospective study has addressed this issue successfully. In this study, the investigators intend to test a novel double pronged method of changing the immune repertoire post ASCT by modifying graft composition and improving effector T cell recovery and function post ASCT. In this study, the investigators intend to generate new information on immune modulation post-ASCT. In addition, the CD38 antibodies have not been evaluated as therapy for B-cell non-Hodgkin Lymphoma (NHL). If this study shows significant immunomodulator activity of this approach, cluster of differentiation 38 (CD38) antibodies could be further evaluated in combination with ASCT in NHL.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Lymphoma Multiple Myeloma Non-Hodgkin Lymphoma Relapsed Hodgkin's Disease, Adult

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Isatuximab and Standard Procedures

Subjects will receive the study drug Isatuximab in addition to standard procedures for transplant

Group Type EXPERIMENTAL

Isatuximab

Intervention Type DRUG

Isatuximab in IV form 10 mg/kg doses

Standard procedures

Subjects will receive standard procedures for transplant.

Group Type EXPERIMENTAL

Standard Procedures

Intervention Type OTHER

Standard procedures (standard of care) for transplant

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Isatuximab

Isatuximab in IV form 10 mg/kg doses

Intervention Type DRUG

Standard Procedures

Standard procedures (standard of care) for transplant

Intervention Type OTHER

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Sarclisa

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Following diagnoses are eligible for inclusion in the study:

A) Multiple Myeloma with ASCT used as consolidation after first line induction therapy or at first relapse.

B) Relapsed/Refractory Hodgkin's disease

C) Non-Hodgkin's Lymphomas as follows
* Relapsed/Refractory Diffuse large B cell lymphoma
* Relapsed/Refractory indolent or relapsed/refractory transformed indolent B cell lymphomas as consolidation after second line therapy
* Mantle Cell lymphoma as consolidation after first-line therapy
* Peripheral T cell lymphoma as consolidation after first-line therapy or at relapse or primary refractory disease
2. Patients undergoing first ASCT will be eligible for the study.
3. Any prior therapy for the malignancy except CD38 antibody within the last 12 months is allowed.
4. Age ≥18 years
5. Life expectancy of greater than 6 months.

Exclusion Criteria

1. Previously exposure to a CD38 antibody during the last 12 months.
2. Participants who are receiving any other investigational agents concurrently or received any investigational agent within the last 8 weeks.
3. History of severe allergic reactions or anaphylaxis attributed to compounds of similar chemical or biologic composition to Isatuximab.
4. Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.
5. Pregnant and Lactating women
6. HIV-positive status due to increased risk of infection when treated with immunosuppressive therapy

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No